Amylx Pharmaceuticals Inc vs iShares Gold Trust — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while iShares Gold Trust trades at $82.74. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, iShares Gold Trust nearer its low. Which is the better fit depends on your goals.
| AMLX | IAU | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $24.19 | $101.57 |
52-Week Low | $7.82 | $62.49 |
Enterprise Value | $2.39B | — |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.35, up 3.0% today, with a bullish technical signal from moving averages. The company reported a net loss of $144.74M in 2025, with negative ROE and ROA, but maintains a strong cash position of $250.8M extending into 2028. Key near-term catalyst is the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, which could drive significant stock movement.
The investment case hinges on successful clinical outcomes; a positive readout may support the consensus price target of $30.00, but persistent losses and high P/B ratio of 11.02 pose risks. Analyst sentiment is overwhelmingly bullish with 91% buy ratings, though recent earnings misses highlight execution challenges.
IAU, the iShares Gold Trust ETF, trades at $82.98 with a 0.57% daily gain amid bullish technical signals from moving averages. The ETF benefits from gold's recent momentum as spot gold reached two-month highs above $4,430/oz following cooling CPI data. While oscillators show bearish signals with RSI at overbought levels, institutional interest remains strong with Deane Retirement Strategies increasing its stake by 36.5% in the latest quarter.
Outlook remains positive as gold gains support from inflation dynamics, geopolitical tensions, and central bank buying. Key risks include potential Fed policy shifts and dollar strength. The 0.25% expense ratio makes IAU attractive for conservative investors seeking gold exposure with lower volatility compared to mining stocks.
Trailing returns across standard periods
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →